Indian pharmaceutical stocks took a hit as Trump’s threat of imposing tariffs on pharma imports spooked investors. Despite India’s strong presence in the US generics market, potential tariffs may increase costs for US consumers and create supply chain challenges.
Expect limited upside in near term, stick to stock-specific strategy; Vedanta, Motherson among top picks: CA Rudramurthy BV
Indian markets are struggling to maintain gains despite positive domestic news. Global factors and foreign selling are creating caution. Short-term traders are advised to reduce
December 10, 2025